R.P. Scherer GmbH & Co
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
R.P. Scherer GmbH & Co - overview
Established
1950
Location
Eberbach, -, Germany
Primary Industry
Pharmaceuticals
About
R. P. Scherer GmbH & Co is a German company specializing in pharmaceutical technology, focusing on innovative delivery forms and solutions for the healthcare industry. Founded in 1950 in Eberbach, Germany, R.
P. Scherer GmbH & Co is engaged in the development of advanced pharmaceutical technologies. The company was involved in a significant deal in February 2012, when Cardinal Health Pharmaceutical Technologies and Services acquired a 49% stake as part of their investment strategy. The firm's operations have been focused on enhancing delivery systems within the healthcare sector.
R. P. Scherer GmbH & Co offers a range of pharmaceutical technologies, specializing in advanced drug delivery systems. Their services include the development and manufacturing of various pharmaceutical formulations designed to optimize therapeutic efficacy.
The company serves a global market, catering to clients in the healthcare sector, including pharmaceutical companies and healthcare providers looking for reliable delivery solutions. In 2013, R. P. Scherer GmbH & Co reported a revenue of USD 131.
94 mn and an EBITDA of USD 14. 15 mn, indicating a strong financial performance in its sector. R. P.
Scherer GmbH & Co plans to expand its product offerings by developing new pharmaceutical delivery systems, with targeted launches expected in the coming years. The company aims to enter additional international markets, focusing on regions such as North America and Asia by 2025. The partnership with Cardinal Health is expected to enhance their capabilities and support these growth initiatives, leveraging additional resources for innovation and market expansion.
Current Investors
Catalent, Inc.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.rpscherer.de
Company Stage
Add-on
Total Amount Raised
Subscriber access only
R.P. Scherer GmbH & Co - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | R.P. Scherer GmbH & Co | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.